Last reviewed · How we verify
FP-025 capsules — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
FP-025 capsules (FP-025 capsules) — Foresee Pharmaceuticals Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FP-025 capsules TARGET | FP-025 capsules | Foresee Pharmaceuticals Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FP-025 capsules CI watch — RSS
- FP-025 capsules CI watch — Atom
- FP-025 capsules CI watch — JSON
- FP-025 capsules alone — RSS
Cite this brief
Drug Landscape (2026). FP-025 capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/fp-025-capsules. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing